**WHAT WE ACHIEVED IN 2015/16**

### TRANSLATION OF PROMISING SCIENTIFIC RESEARCH

- **£185M** additional investment raised by CRT spin-out companies
- **£29M** leveraged in industrial and external grant support for CRUK researchers
- **£20M** profit from CRT returned to CRUK to fund further research

### BUILT INNOVATIVE ALLIANCES IN OUR DRUG DISCOVERY LABS

- **3rd project from our Deubiquitinase Alliance** with Forma Therapeutics entered lead optimisation, advancing towards clinical trials
- **Alliance established** with Merck KGaA to explore target validation and assay build within the Hippo pathway, one that is often de-regulated in cancers of high unmet need

### DELIVERED PATIENT BENEFIT

- **£29M** leveraged in industrial and external grant support for CRUK researchers
- **£20M** profit from CRT returned to CRUK to fund further research

### DROVE INVESTMENT TO PROGRESS CANCER RESEARCH

- **38** total number of drugs in clinic
- **8 licences completed** for the IBIS breast cancer risk assessment tool this year, taking the total number of licences to **17**
- **A 2nd product advanced to clinical trials** from our CEA antibody programme licensed to Roche

### Values based on data from 1st April 2015 – 31st March 2016

cancertech.com